Subscribe To

Price Alert Latest News Economic Calendar News

MRNS / Marinus Pharmaceuticals stock surges on financial guidance

Marinus (NASDAQ:MRNS) Pharmaceuticals Inc shares climbed 20% to $7.02 on Tuesday after the pharmaceutical company dedicated to the development of therapeutics to treat seizure disorders revealed highlights from its Investor and Analyst Event in New York. Marinus said it expects third quarter 2023 ZTALMY (ganaxolone) oral suspension CV net product revenues of between $5 million and $5.2 million and is on track to meet full year 2023 expected ZTALMY net product revenues of between $17 million and $18.5 million. Read More

Demo Live Account See Partner Details

Content Topics

Marinus

Pharmaceuticals

Stock

Surges

Financial

Guidance

MRNS

Posted: Sep 19 2023, 15:57

Author Name: Proactive Investors

MRNS News

By Business Wire
October 24, 2023

Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the develop

By Zacks Investment Research
September 20, 2023

Marinus (MRNS) Up 20% on Financial and Pipeline Updates

Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline

By Zacks Investment Research
September 20, 2023

Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock?

Marinus Pharmaceuticals (MRNS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mig

By Proactive Investors
September 19, 2023

Marinus Pharmaceuticals stock surges on financial guidance

Marinus (NASDAQ:MRNS) Pharmaceuticals Inc shares climbed 20% to $7.02 on Tuesday after the pharmaceutical company dedicated to the development of ther

By Business Wire
July 27, 2023

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therap

By Zacks Investment Research
July 3, 2023

Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength?

Marinus Pharmaceuticals (MRNS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate rev

By Seeking Alpha
June 22, 2023

Marinus: Transforming The Seizure Market With Ganaxolone (Rating Upgrade)

Marinus Pharmaceuticals has pivoted from postpartum depression to focus on seizure disorders, leading to FDA approval for Ztalmy (ganaxolone) for trea

By Zacks Investment Research
May 11, 2023

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates

Marinus Pharmaceuticals (MRNS) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.